X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3028) 3028
Publication (471) 471
Newsletter (38) 38
Book Review (24) 24
Magazine Article (9) 9
Book Chapter (8) 8
Dissertation (7) 7
Newspaper Article (6) 6
Conference Proceeding (4) 4
Data Set (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2155) 2155
lopinavir (1874) 1874
hiv infections - drug therapy (1614) 1614
index medicus (1369) 1369
infectious diseases (1260) 1260
male (1241) 1241
female (1226) 1226
adult (1096) 1096
ritonavir (914) 914
hiv (897) 897
pharmacology & pharmacy (779) 779
ritonavir - therapeutic use (741) 741
middle aged (706) 706
antiretroviral therapy (681) 681
lopinavir/ritonavir (680) 680
immunology (668) 668
protease inhibitors (647) 647
hiv protease inhibitors - therapeutic use (641) 641
anti-hiv agents - therapeutic use (614) 614
ritonavir - administration & dosage (545) 545
hiv infections - virology (538) 538
pyrimidinones - therapeutic use (536) 536
virology (503) 503
drug therapy, combination (498) 498
viral load (490) 490
treatment outcome (451) 451
microbiology (432) 432
antiviral agents (415) 415
hiv-1 - drug effects (407) 407
pharmacokinetics (407) 407
anti-hiv agents - administration & dosage (394) 394
hiv protease inhibitors - administration & dosage (390) 390
ritonavir - adverse effects (380) 380
drug therapy (379) 379
pyrimidinones - administration & dosage (357) 357
therapy (353) 353
hiv infection (350) 350
human immunodeficiency virus--hiv (347) 347
cd4 lymphocyte count (336) 336
hiv protease inhibitors - adverse effects (333) 333
antiretroviral drugs (319) 319
efavirenz (306) 306
highly active antiretroviral therapy (301) 301
lopinavir - therapeutic use (298) 298
drug combinations (295) 295
tenofovir (294) 294
anti-hiv agents - adverse effects (289) 289
hiv-1 (288) 288
antiretroviral therapy, highly active (283) 283
aids/hiv (270) 270
pyrimidinones - adverse effects (268) 268
ritonavir - pharmacokinetics (267) 267
efficacy (256) 256
safety (253) 253
atazanavir sulfate (252) 252
drug interactions (252) 252
research (252) 252
hiv protease inhibitors - pharmacokinetics (248) 248
atazanavir (246) 246
aids (245) 245
adolescent (244) 244
health aspects (240) 240
hiv protease inhibitors - pharmacology (234) 234
virus diseases (229) 229
young adult (226) 226
dosage and administration (225) 225
protease inhibitor (225) 225
article (222) 222
drug administration schedule (216) 216
anti-hiv agents - pharmacokinetics (212) 212
hiv-1 - genetics (212) 212
analysis (210) 210
pyrimidinones - pharmacokinetics (209) 209
lopinavir - administration & dosage (206) 206
risk factors (203) 203
nevirapine (202) 202
darunavir (199) 199
ritonavir - pharmacology (195) 195
proteases (191) 191
hiv infections - blood (189) 189
human-immunodeficiency-virus (189) 189
infection (189) 189
nelfinavir (187) 187
hiv infections - complications (186) 186
active antiretroviral therapy (185) 185
hiv-1-infected patients (185) 185
rna, viral - blood (185) 185
lamivudine (184) 184
prospective studies (182) 182
combination (180) 180
reverse transcriptase inhibitors - therapeutic use (179) 179
aged (178) 178
hiv-infected patients (178) 178
saquinavir (178) 178
drug resistance, viral (171) 171
mutation (170) 170
pregnancy (168) 168
resistance (168) 168
drugs (167) 167
pyrimidinones - pharmacology (167) 167
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2913) 2913
Spanish (103) 103
German (33) 33
French (21) 21
Russian (10) 10
Japanese (8) 8
Chinese (3) 3
Italian (3) 3
Portuguese (3) 3
Czech (1) 1
Serbian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Pediatric Infectious Disease Journal, ISSN 0891-3668, 2014, Volume 33, Issue 3, pp. 301 - 305
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 2014, Volume 69, Issue 5, pp. 1390 - 1396
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1726 - 1737
In this randomized, controlled trial in Africa and India, combination antiretroviral therapy was more effective than standard therapy in preventing... 
PRETERM DELIVERY | CHILD-MORTALITY | MEDICINE, GENERAL & INTERNAL | TENOFOVIR DISOPROXIL FUMARATE | INFECTED WOMEN | PROGESTERONE LEVELS | ADVERSE BIRTH OUTCOMES | LOPINAVIR/RITONAVIR | LOPINAVIR EXPOSURE | PROTEASE | PREGNANCY | HIV Infections - prevention & control | Infant Mortality | Humans | African Americans | Perinatal Care | Infant | Young Adult | Adult | Female | HIV Infections - transmission | Drug Therapy, Combination | Infant, Newborn | Infant, Low Birth Weight | Anti-Retroviral Agents - therapeutic use | Tenofovir - therapeutic use | Zidovudine - adverse effects | Anti-Retroviral Agents - adverse effects | CD4 Lymphocyte Count | Gestational Age | Pregnancy | Infant, Premature | Zidovudine - therapeutic use | HIV Infections - ethnology | Nevirapine - administration & dosage | Infectious Disease Transmission, Vertical - prevention & control | Pregnancy Outcome | Prevention | Highly active antiretroviral therapy | Complications and side effects | Care and treatment | Nevirapine | Pregnant women | HIV patients | Dosage and administration | Research | HIV (Viruses) | Zidovudine | Health aspects | Emtricitabine | Neonates | Antiretroviral drugs | Breastfeeding & lactation | Ritonavir | Lopinavir | Lamivudine | Infants | Gestation | Antiretroviral therapy | Postpartum | CD4 antigen | Disease prevention | Tenofovir | Cost-benefit analysis | Disease transmission | Maternal & child health | Human immunodeficiency virus--HIV | Birth weight | Drug therapy
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, p. e0171611
Objective The primary objective of this study was to estimate the incidence of treatment failure (TF) to protease inhibitor monotherapies (Pl/r-MT) with... 
GLOMERULAR-FILTRATION-RATE | REVERSE-TRANSCRIPTASE INHIBITORS | EFFECTIVE ANTIRETROVIRAL THERAPY | MYOCARDIAL-INFARCTION | MULTIDISCIPLINARY SCIENCES | PROTEASE INHIBITOR MONOTHERAPY | LOPINAVIR-RITONAVIR MONOTHERAPY | INCOMPLETE REVERSIBILITY | MONET TRIAL | HIV-1-INFECTED PATIENTS | COHORT COLLABORATION | Outcome Assessment (Health Care) - methods | Humans | Middle Aged | Male | HIV - drug effects | Viral Load | Young Adult | RNA, Viral - genetics | Ritonavir - therapeutic use | Adult | Female | Antiretroviral Therapy, Highly Active - methods | Drug Therapy, Combination | HIV Infections - virology | Kaplan-Meier Estimate | Proportional Hazards Models | Viremia - genetics | CD4 Lymphocyte Count | HIV Protease Inhibitors - therapeutic use | Outcome Assessment (Health Care) - statistics & numerical data | HIV - genetics | HIV Infections - drug therapy | Lopinavir - therapeutic use | Viremia - blood | Darunavir - therapeutic use | Cohort Studies | Antiviral agents | RNA | Ritonavir | Analysis | Dosage and administration | Research | HIV infection | Antiretroviral drugs | Therapy | Viremia | Lopinavir | Regression analysis | Criteria | Ribonucleic acid--RNA | Medical diagnosis | Patients | Reintroduction | Data bases | CD4 antigen | Studies | Infectious diseases | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Hemoglobin | Data collection | Drug therapy | Failure | Deoxyribonucleic acid--DNA | Acquired immune deficiency syndrome | Deoxyribonucleic acid | Ribonucleic acid | AIDS | HIV | DNA | Human immunodeficiency virus
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 234 - 247
Journal Article